Table 2.
Variables associated with clinical outcome
| Locoregional recurrence-free survival (LRRS) | |||
|---|---|---|---|
| Univariate | Multivariate | ||
| ≥10 positive lymph nodes | p = 0.017 | ≥10 positive lymph nodes | p = 0.020 |
| Low Gal3 | p = 0.034 | ||
| Disease-specific survival (DSS) | |||
| Univariate | Multivariate | ||
| Low Gal3 | p = 0.018 | Low Gal3 | p = 0.003 p = 0.003 |
| Her2 IHC score | p = 0.008 | HER2 IHC score | |
| Race | p = 0.030 | ||
| Overall survival (OS) | |||
| Univariate | Multivariate | ||
| Low Gal3 | p = 0.019 | Low Gal3 | p = 0.014 |
| Her2 IHC score | p = 0.015 | HER2 IHC score | p = 0.001 |
Gal3 galectin-3, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry